Biosimilars Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Filgrastim & Peg-filgrastim, Monoclonal Antibodies, and Others), By Disease Indication (Cancer, Autoimmune Diseases {Arthritis, Psoriasis, and Others}, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2026-2034

ATTRIBUTE

DETAILS

Study Period

2021-2034

Base Year

2025

Estimated Year 

2026

Forecast Period

2026-2034

Historical Period

2021-2024

Growth Rate

CAGR of 17.3% from 2026 to 2034

Unit

Value (USD Billion)

Segmentation

By Drug Class

• Filgrastim & Peg-filgrastim
• Monoclonal Antibodies
• Others

By Disease Indication

• Cancer
• Autoimmune Diseases
  • Arthritis
  • Psoriasis
  • Others
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America (By Drug Class, Disease Indication, Distribution Channel, and Country/Sub-Region)
  • U.S. (By Drug Class)
  • Canada (By Drug Class)
• Europe (By Drug Class, Disease Indication, Distribution Channel, and Country/ Sub-Region)
  • U.K. (By Drug Class)
  • Germany (By Drug Class)
  • France (By Drug Class)
  • Italy (By Drug Class)
  • Spain (By Drug Class)
  • Scandinavia (By Drug Class)
  • Rest of Europe (By Drug Class)
• Asia Pacific (By Drug Class, Disease Indication, Distribution Channel, and Country/ Sub-Region)
  • China (By Drug Class)
  • India (By Drug Class)
  • Japan (By Drug Class)
  • Australia (By Drug Class)
  • Southeast Asia (By Drug Class)
  • Rest of Asia Pacific (By Drug Class)
• Latin America (By Drug Class, Disease Indication, Distribution Channel, and Country/ Sub-Region)
  • Brazil (By Drug Class)
  • Mexico (By Drug Class)
  • Rest of Latin America (By Drug Class)
• Middle East & Africa (By Drug Class, Disease Indication, Distribution Channel, and Country/ Sub-Region)
  • GCC (By Drug Class)
  • South Africa (By Drug Class)
  • Rest of the Middle East & Africa (By Drug Class)